GLMD Galmed Pharma Forward P/S Multiple

Galmed Pharmaceuticals develops liver therapies utilizing the capacities of European CMO contractors. The forward P/S trend helps assess market expectations, where the level reflects the current magnitude. The issuer's revenues are based on investments and partnerships in the treatment of fatty degeneration. However, a speculative profile and the absence of commercial products amid fierce competition weaken the company's market position.

GLMD Galmed Pharmaceuticals Ltd: Price-to-Projected Revenue Ratio in the range 07/04/2022 - 11/15/2026

GLMD (Galmed Pharmaceuticals Ltd.): analytical breakdowns and indicator data

- current price and projected stock value:

Stock Price Galmed Pharma|GLMD - Analyst Target Range

- market capitalization data:

Market Capitalization Galmed Pharmaceuticals|GLMD - Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Galmed Pharmaceuticals|GLMD - Company Book Value|Market Value to Book Value Ratio galmedpharma.com|GLMD - Cumulative Company Assets

- issuer credit burden and liquidity indicators:

- business earnings and investment ratios data:

GLMD - Final Profit|Projected Future Earnings Galmed Pharmaceuticals|GLMD - P/E Multiple|Future Price to Earnings Galmed Pharmaceuticals|GLMD - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galmed Pharmaceuticals Ltd|GLMD - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Galmed Pharmaceuticals|GLMD - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth galmedpharma.com|GLMD - Net earnings per share growth this year|Earnings growth forecast for next year Galmed Pharmaceuticals

- sales revenue and business income indicators:

GLMD - Company Total Revenue|Company Future Sales Volume Galmed Pharmaceuticals Ltd|GLMD - P/S Multiple|Forward Price-to-Revenue Multiple Galmed Pharmaceuticals|GLMD - Revenue Change YoY (Last 12 Months)

Fundamental company valuation:Galmed Pharmaceuticals Ltd. (GLMD)

The forward P/S ratio measures the current market value of Galmed Pharmaceuticals (GLMD) relative to projected revenue, allowing investors to assess the extent of expectations priced in under tight monetary policy. By analyzing the projected P/S multiple, one can determine whether the market is fairly valuing the commercialization potential of liver drug patents and future licensing revenues from global partners.

Key competitors

Forward P/S Multiple ARWR (Arrowhead Pharma)|MIRM - Forward Price-to-Revenue Multiple|DVAX: Forward Price-to-Revenue Multiple|Forward Price to Sales ABUS (Arbutus Biopharma)|IVA: Forward P/S Multiple|Gyre Therapeutics - Forward Price to Sales|ASMB (assemblybio.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Galectin Therapeutics GALT|Forward P/S Multiple GNFT|Forward Price-to-Revenue Multiple DURECT Corp. DRRX|Price-to-Projected Revenue Ratio aligos.com ALGS|biovieinc.com (BIVI) - Market Cap to Future Revenue Ratio|NDRA - Price-to-Projected Revenue Ratio|Forward Price to Sales HEPA (Hepion Pharmaceuticals, Inc.)